Related Experiment Video
Updated: Apr 27, 2026
Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
Published on: April 10, 2020
Anti-cancer drug discovery: update and comparisons in yeast, Drosophila, and zebrafish
Guangxun Gao, Liang Chen, Chuanshu Huang1
1Nelson Institute of Environmental Medicine, New York University School of Medicine, 57 Old Forge Road, Tuxedo, NY 10987, USA. chuanshu.huang@nyumc.org.
Abstract:
Discovery of novel cancer chemotherapeutics focuses on screening and identifying compounds that can target 'cancer-specific' biological processes while causing minimal toxicity to non-tumor cells. Alternatively, model organisms with highly conserved cancer-related cellular processes relative to human cells may offer new opportunities for anticancer drug discovery when combined with chemical screening. Some organisms used for chemotherapeutic discovery include yeast, Drosophila, and zebrafish which are similar in important ways relevant to cancer study but offer distinct advantages as well. Here, we describe these model attributes and the rationale for using them in cancer drug screening research.
Insights
Researchers are exploring model organisms like yeast, Drosophila, and zebrafish for novel anticancer drug discovery. These models share conserved cancer pathways with humans, aiding in identifying effective chemotherapeutics with reduced toxicity.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Novel cancer chemotherapeutics require targeting cancer-specific processes with minimal host toxicity.
- Model organisms offer conserved cellular pathways relevant to human cancer research.
- Organisms such as yeast, Drosophila, and zebrafish present unique advantages for drug screening.
Purpose of the Study:
- To highlight the utility of model organisms in anticancer drug discovery.
- To explain the rationale for employing these models in chemical screening.
- To discuss the specific attributes of yeast, Drosophila, and zebrafish for cancer research.
Main Methods:
- Reviewing and synthesizing existing research on model organism use in cancer drug discovery.
- Comparing conserved cancer-related cellular processes across different model organisms.
- Analyzing the advantages and disadvantages of each model for chemotherapeutic screening.
Main Results:
- Model organisms possess conserved biological pathways crucial for cancer development and progression.
- Yeast, Drosophila, and zebrafish exhibit distinct yet complementary advantages for high-throughput chemical screening.
- These models facilitate the identification of compounds targeting cancer-specific mechanisms with potentially lower off-target effects.
Conclusions:
- Model organisms provide a powerful and cost-effective platform for identifying novel anticancer chemotherapeutics.
- Utilizing diverse model systems enhances the scope and efficiency of drug discovery pipelines.
- Further research into model organism-based screening can accelerate the development of targeted cancer therapies.
